RhoVac’s Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDA
Lund, Sweden, November 25, 2020: RhoVac, a clinical stage company today announced that the American FDA has granted Fast Track Designation to the company’s drug candidate, RV001. Fast Track Designation is granted to investigational drugs for expedited review by the FDA, to facilitate development of drugs aimed at treating serious or life-threatening conditions and fill unmet medical needs.The granted Fast Track Designation means that Rhovac and RV001 are eligible for the following: · More frequent meetings with FDA to discuss the drug's development plan and ensure collection of